AMLX
VENTE TOTALE: 60 928 titres (~1 958 378,24 $ US)
- Insiders
- Klee Justin B., Cohen Joshua B
- Total bought
- —
- Total sold
- $1,958,378
- Last activity
- 2026-09-10
- Last synced
-
2026-09-15 10:12:06
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signal Scored 2026-09-14
AMLX presents a deeply unfavorable risk/reward profile: zero revenue, persistent negative cash flows, and a near-rock-bottom fundamental trend score of 15 overwhelm the company's relatively solid liquidity buffer.
The first sentence of the analysis written for AMLX on 2026-09-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 51.8% | 93.3% | 86.5% | 0.0% | |
| Ebit Margin | 0.0% | -334.1% | 14.3% | -888.9% | 0.0% | |
| Ebitda Margin | 0.0% | -333.0% | 14.5% | -886.7% | 0.0% | |
| Operating Profit Margin | 0.0% | -360.2% | 10.2% | -905.7% | 0.0% | |
| Pretax Profit Margin | 0.0% | -345.8% | 14.3% | -888.9% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Net Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Current Ratio | 14.266 | 6.669 | 5.664 | 8.199 | 6.033 | |
| Quick Ratio | 14.266 | 6.669 | 5.197 | 7.989 | 6.033 | |
| Solvency Ratio | -5.266 | -10.421 | 0.599 | -3.892 | -0.342 | |
| Cash Ratio | 9.990 | 2.724 | 2.075 | 1.342 | 2.885 | |
| Price To Earnings Ratio | -7.895 | -0.853 | 20.164 | -12.399 | -11.888 | |
| Price To Earnings Growth Ratio | 0.121 | 0.001 | -0.162 | -0.129 | -0.129 | |
| Forward Price To Earnings Growth Ratio | 0.121 | 0.001 | -0.162 | -0.129 | -0.129 | |
| Price To Earnings Diluted Ratio | -7.895 | -0.853 | 21.029 | -12.399 | -11.888 | |
| Price To Earnings Diluted Growth Ratio | 0.121 | 0.001 | -0.170 | -0.129 | -0.129 | |
| Price To Book Ratio | 3.742 | 1.563 | 2.283 | 7.215 | -6.917 | |
| Price To Sales Ratio | 0.000 | 2.948 | 2.599 | 110.554 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.251 | -1.535 | 92.685 | -13.474 | -13.913 | |
| Price To Operating Cash Flow Ratio | -9.262 | -1.536 | 83.035 | -13.663 | -13.979 | |
| Debt To Assets Ratio | 0.018 | 0.010 | 0.008 | 0.016 | 0.000 | |
| Debt To Equity Ratio | 0.020 | 0.012 | 0.010 | 0.018 | 0.000 | |
| Debt To Capital Ratio | 0.019 | 0.012 | 0.010 | 0.018 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.015 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.175 | 1.194 | 1.149 | -0.699 | |
| Working Capital Turnover Ratio | 0.000 | 0.321 | 1.060 | 0.105 | 0.000 | |
| Operating Cash Flow Ratio | -5.436 | -5.902 | 0.145 | -3.859 | -4.300 | |
| Operating Cash Flow Sales Ratio | 0.000 | -1.919 | 0.031 | -8.091 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 0.896 | 1.014 | 1.005 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -20.706 | -84.627 | 2.813 | -28.656 | 0.000 | |
| Capital Expenditure Coverage Ratio | -893.790 | -1,067.815 | 9.604 | -71.208 | -211.895 | |
| Dividend Paid And Capex Coverage Ratio | -893.790 | -1,067.815 | 9.604 | -71.208 | -211.895 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.393 | -0.626 | 14.873 | -12.183 | -11.327 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-51.7% | ▼-46.3% |
| Ebit Margin | 0.0% | ▲334.1% | ▲241.7% |
| Ebitda Margin | 0.0% | ▲333.0% | ▲241.0% |
| Operating Profit Margin | 0.0% | ▲360.2% | ▲251.1% |
| Pretax Profit Margin | 0.0% | ▲345.8% | ▲244.1% |
| Continuous Operations Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Net Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Bottom Line Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Current Ratio | 14.266 | ▲7.597 | ▲6.100 |
| Quick Ratio | 14.266 | ▲7.597 | ▲6.235 |
| Solvency Ratio | -5.266 | ▲5.155 | ▼-1.401 |
| Cash Ratio | 9.990 | ▲7.265 | ▲6.187 |
| Price To Earnings Ratio | -7.895 | ▼-7.042 | ▼-5.321 |
| Price To Earnings Growth Ratio | 0.121 | ▲0.119 | ▲0.180 |
| Forward Price To Earnings Growth Ratio | 0.121 | ▲0.119 | ▲0.180 |
| Price To Earnings Diluted Ratio | -7.895 | ▼-7.042 | ▼-5.494 |
| Price To Earnings Diluted Growth Ratio | 0.121 | ▲0.119 | ▲0.182 |
| Price To Book Ratio | 3.742 | ▲2.179 | ▲2.165 |
| Price To Sales Ratio | 0.000 | ▼-2.948 | ▼-23.220 |
| Price To Free Cash Flow Ratio | -9.251 | ▼-7.716 | ▼-20.154 |
| Price To Operating Cash Flow Ratio | -9.262 | ▼-7.725 | ▼-18.180 |
| Debt To Assets Ratio | 0.018 | ▲0.008 | ▲0.007 |
| Debt To Equity Ratio | 0.019 | ▲0.007 | ▲0.008 |
| Debt To Capital Ratio | 0.019 | ▲0.007 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.015 | ▲0.015 | ▲0.012 |
| Financial Leverage Ratio | 1.090 | ▼-0.086 | ▲0.308 |
| Working Capital Turnover Ratio | 0.000 | ▼-0.321 | ▼-0.297 |
| Operating Cash Flow Ratio | -5.436 | ▲0.465 | ▼-1.566 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲1.919 | ▲1.996 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.000 | ▲0.018 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -20.706 | ▲63.922 | ▲5.529 |
| Capital Expenditure Coverage Ratio | -893.790 | ▲174.025 | ▼-446.769 |
| Dividend Paid And Capex Coverage Ratio | -893.790 | ▲174.025 | ▼-446.769 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.393 | ▼-5.767 | ▼-3.262 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.14B | $257.6M | $989.7M | $2.46B | $1.05B | |
| Enterprise value | $921.7M | $182.2M | $823.7M | $2.40B | $995.4M | |
| EV / Sales | 0.00x | 2.08x | 2.16x | 108.02x | 0.00x | |
| EV / Op. cash flow | -7.47x | -1.09x | 69.11x | -13.35x | -13.31x | |
| EV / Free cash flow | -7.46x | -1.09x | 77.14x | -13.17x | -13.24x | |
| EV / EBITDA | -6.39x | -0.63x | 14.87x | -12.18x | -11.33x | |
| Net debt / EBITDA | 1.53x | 0.26x | -3.00x | 0.28x | 0.57x | |
| Current ratio | 14.27x | 6.67x | 5.66x | 8.20x | 6.03x | |
| Income quality | 0.85x | 0.56x | 0.24x | 0.91x | 0.85x | |
| Graham number | — | — | $10 | — | — | |
| Graham net-net | $3 | $2 | $5 | $5 | -$3 | |
| Tax burden | 100.0% | 99.9% | 90.7% | 100.4% | 100.0% | |
| Interest burden | 100.0% | 103.5% | 100.0% | 100.0% | 100.0% | |
| Working capital | $301.0M | $161.0M | $382.6M | $335.5M | $87.6M | |
| Invested capital | $306.5M | $163.8M | $389.0M | $343.7M | $88.0M | |
| Return on assets | -43.5% | -155.8% | 9.5% | -50.7% | -83.3% | |
| Operating ROA | -58.3% | -88.5% | 8.5% | -81.0% | -138.1% | |
| Return on tangible assets | -43.5% | -155.8% | 9.5% | -50.7% | -83.3% | |
| Return on equity | -47.4% | -183.1% | 11.4% | -58.2% | 58.2% | |
| Return on invested capital | -49.3% | -188.5% | 8.0% | -58.0% | -93.7% | |
| Return on capital employed | -49.5% | -190.5% | 8.9% | -58.4% | -93.7% | |
| Earnings yield | -12.7% | -117.1% | 5.0% | -8.1% | -8.4% | |
| Free cash flow yield | -10.8% | -65.1% | 1.1% | -7.4% | -7.2% | |
| Capex / Op. cash flow | -0.1% | -0.1% | 10.4% | -1.4% | -0.5% | |
| Capex / Depreciation | 26.3% | 17.4% | 114.1% | 518.7% | 678.8% | |
| Capex / Sales | 0.0% | 0.2% | 0.3% | 11.4% | 0.0% | |
| SG&A / Sales | 0.0% | 130.9% | 49.5% | 571.9% | 0.0% | |
| R&D / Sales | 0.0% | 119.1% | 33.7% | 420.4% | 0.0% | |
| Stock comp / Sales | 0.0% | 37.8% | 9.8% | 97.7% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 2d | 38d | 251d | 0d | |
| Days payables outstanding | 2447d | 25d | 317d | 763d | 0d | |
| Operating cycle | 0d | 2d | 588d | 1443d | 0d | |
| Cash conversion cycle | -2447d | -24d | 272d | 680d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+343.5%EV / Sales ▼-100.0%EV / EBITDA ▼-921.2%EV / Op. cash flow ▼-6.386Earnings yield ▲+1.045
Profitability
Return on equity ▲+1.357Return on assets ▲+1.123Return on invested capital ▲+1.392Return on capital employed ▲+1.410Operating ROA ▲+0.303Income quality ▲+0.297Tax burden ▲+0.002
Efficiency
Days sales outstanding ▼-1.867Days payables outstanding ▲+2421.096Operating cycle ▼-1.867Cash conversion cycle ▼-2422.963Capex / Sales ▼-0.002R&D / Sales ▼-1.191
Balance-sheet strength
Current ratio ▲+7.597Net debt / EBITDA ▲+1.272Working capital ▲+139957000.000Invested capital ▲+142716000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+9.3%EV / Sales n/aEV / EBITDA ▲+43.6%EV / Op. cash flow ▲+5.836Earnings yield ▼-0.043
Profitability
Return on equity ▼-1.056Return on assets ▲+0.397Return on invested capital ▲+0.445Return on capital employed ▲+0.443Operating ROA ▲+0.799Income quality ▲+0.002Tax burden +0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+8.233Net debt / EBITDA ▲+0.960Working capital ▲+213428000.000Invested capital ▲+218445000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-10-12 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-10 Better Healthcare ETF: Vanguard''s VHT vs. State Street''s Pharmaceuticals-Focused XPH Vanguard''s broader healthcare portfolio charges less and yields more, but State Street''s pharma-focused fund has delivered stronger recent gains despite higher volatility.
- 2026-09-10 Which Healthcare ETF Is the Better Buy: Fidelity''s Broad FHLC or State Street''s Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
- 2026-09-01 Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company''s next catalyst.
- 2026-08-29 BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company''s stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
- 2026-08-29 BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company''s stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
- 2026-08-27 20 stocks likely to lose money even if the bull market continues Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
- 2026-08-27 Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 974,881 shares of the company''s stock, valued at approximately $17,509,000. Amylyx Pharmaceuticals comprises approximately 4.2% of Almitas
- 2026-08-24 Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company''s stock, valued at approximately $10,021,000. Deutsche Bank AG owned 0.50% of Amylyx Pharmaceuticals at the end of the most
- 2026-08-21 Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
- 2026-08-20 Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (âAmylyxâ or the âCompanyâ) today announced the pricing of an upsized underwritten public offering of 14,090